View the article here

___

Abbreviations: AEMPS: Spanish Agency of Medicines and Medical Devices; AIHTA: Austrian Institute for Health Technology Assessment; AOTMiT: Agency for Health Technology Assessment and Tariff System ; ATMP: Advanced Therapy Medicinal Product; CHMP: Committee for Medicinal Products for Human Use; DMC: Danish Medicines Council; DVSV: Federation of Social Insurances; EMA: European Medicines Agency; EU: European Union; GVD: Global Value Dossier; HAS: National Authority for Health; HEOR: Health Economics and Outcomes Research; HTA: Health Technology Assessment; HTA: EU Health Technology Assessment Regulation; HTD: Health Technology Developer; INFARMED: National Authority of Medicines and Health Products; IQWiG: Institute for Quality and Efficiency in Health Care; ITC; Indirect Treatment Comparison; IZIV-INAMI: National Institute for Health and Disability; JAZMP: Public Agency for Quality in Healthcare; JCA: Joint Clinical Assessment; NCPE: National Centre for Pharmacoeconomics; NIHDI-INAMI-RIZIV: National Institute for Health and Disability Insurance; NIHO: National Institute for Value and Technology in Health; MA: Marketing Authorisation; MS: Member State; NNGYK: National Centre for Public Health and Pharmacy; NOMA: Norwegian Medical Products Agency; PICO: Population, Intervention, Comparator, Outcome; RCT: Randomised Controlled Trial; RWE: Real World Evidence; SMA: Spinal Muscular Atrophy; TLV: Dental and Pharmaceutical Benefits Agency; ZIN: Dutch National Health Care Institute